Name | Number of supported studies | Average coverage | |
---|---|---|---|
fibroblast | 20 studies | 28% ± 14% | |
smooth muscle cell | 19 studies | 30% ± 11% | |
pericyte | 18 studies | 27% ± 11% | |
ciliated cell | 14 studies | 29% ± 10% | |
astrocyte | 12 studies | 40% ± 15% | |
endothelial cell | 10 studies | 31% ± 11% | |
basal cell | 9 studies | 27% ± 11% | |
myofibroblast cell | 8 studies | 32% ± 11% | |
retinal cone cell | 8 studies | 51% ± 19% | |
oligodendrocyte precursor cell | 8 studies | 38% ± 16% | |
retinal rod cell | 7 studies | 40% ± 12% | |
GABAergic neuron | 6 studies | 38% ± 19% | |
connective tissue cell | 6 studies | 24% ± 6% | |
type I pneumocyte | 6 studies | 22% ± 3% | |
type II pneumocyte | 6 studies | 29% ± 6% | |
microglial cell | 6 studies | 28% ± 12% | |
epithelial cell | 5 studies | 28% ± 8% | |
cardiac muscle cell | 5 studies | 30% ± 6% | |
Mueller cell | 5 studies | 45% ± 12% | |
endothelial cell of lymphatic vessel | 5 studies | 25% ± 4% | |
club cell | 5 studies | 25% ± 5% | |
retinal pigment epithelial cell | 4 studies | 37% ± 20% | |
glutamatergic neuron | 4 studies | 41% ± 17% | |
interneuron | 4 studies | 38% ± 19% | |
myoepithelial cell | 4 studies | 37% ± 16% | |
ionocyte | 3 studies | 24% ± 1% | |
secretory cell | 3 studies | 18% ± 2% | |
muscle cell | 3 studies | 44% ± 34% | |
respiratory goblet cell | 3 studies | 24% ± 6% | |
neuron | 3 studies | 23% ± 8% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 7165.26 | 1445 / 1445 | 100% | 16.40 | 183 / 183 |
skin | 99% | 2558.52 | 1795 / 1809 | 99% | 23.22 | 469 / 472 |
ovary | 100% | 8444.55 | 180 / 180 | 98% | 16.20 | 423 / 430 |
lung | 100% | 3516.36 | 576 / 578 | 98% | 12.95 | 1130 / 1155 |
intestine | 100% | 6947.92 | 965 / 966 | 97% | 9.83 | 512 / 527 |
stomach | 100% | 5862.59 | 359 / 359 | 97% | 10.92 | 276 / 286 |
thymus | 100% | 3554.32 | 652 / 653 | 96% | 15.64 | 579 / 605 |
pancreas | 98% | 1905.05 | 321 / 328 | 97% | 14.50 | 173 / 178 |
uterus | 100% | 16967.95 | 170 / 170 | 95% | 15.68 | 434 / 459 |
brain | 94% | 1755.42 | 2471 / 2642 | 99% | 16.36 | 701 / 705 |
breast | 96% | 3539.80 | 441 / 459 | 93% | 10.13 | 1035 / 1118 |
prostate | 100% | 5504.79 | 245 / 245 | 87% | 8.13 | 439 / 502 |
bladder | 100% | 7159.33 | 21 / 21 | 85% | 9.45 | 429 / 504 |
kidney | 98% | 2563.06 | 87 / 89 | 85% | 7.25 | 767 / 901 |
adrenal gland | 100% | 7075.31 | 258 / 258 | 77% | 6.83 | 176 / 230 |
liver | 95% | 1536.55 | 214 / 226 | 68% | 5.27 | 275 / 406 |
spleen | 100% | 6300.37 | 241 / 241 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 4793.95 | 1334 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 99% | 20.28 | 79 / 80 |
adipose | 94% | 2681.79 | 1135 / 1204 | 0% | 0 | 0 / 0 |
heart | 94% | 2671.16 | 810 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 93% | 14.67 | 42 / 45 |
muscle | 65% | 874.32 | 518 / 803 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 17% | 0.70 | 5 / 29 |
peripheral blood | 0% | 2.95 | 1 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0070374 | Biological process | positive regulation of ERK1 and ERK2 cascade |
GO_0005938 | Cellular component | cell cortex |
GO_0005886 | Cellular component | plasma membrane |
GO_0055037 | Cellular component | recycling endosome |
GO_0005085 | Molecular function | guanyl-nucleotide exchange factor activity |
GO_0005515 | Molecular function | protein binding |
Gene name | DENND2B |
Protein name | DENN domain-containing protein 2B (HeLa tumor suppression 1) (Suppression of tumorigenicity 5 protein) DENN domain containing 2B DENN domain containing 2B (cDNA FLJ55510, highly similar to Suppression of tumorigenicity 5) |
Synonyms | HTS1 ST5 |
Description | FUNCTION: [Isoform 1]: May be involved in cytoskeletal organization and tumorogenicity. Seems to be involved in a signaling transduction pathway leading to activation of MAPK1/ERK2. Plays a role in EGFR trafficking from recycling endosomes back to the cell membrane . .; FUNCTION: [Isoform 2]: Guanine nucleotide exchange factor (GEF) which may activate RAB9A and RAB9B. Promotes the exchange of GDP to GTP, converting inactive GDP-bound Rab proteins into their active GTP-bound form. .; FUNCTION: [Isoform 3]: May block ERK2 activation stimulated by ABL1 (Probable). May alter cell morphology and cell growth (Probable). . |
Accessions | E9PLR2 E9PI72 ENST00000530438.5 [P78524-2] E9PNX7 ENST00000531060.1 ENST00000626808.2 ENST00000533580.5 E9PLB6 ENST00000526757.5 [P78524-2] ENST00000526126.5 P78524 E9PI58 ENST00000533681.5 ENST00000524757.5 ENST00000525169.5 ENST00000526241.5 E9PLH5 ENST00000534278.5 ENST00000527930.5 E9PLD7 E9PPL2 E9PKE0 ENST00000526828.5 E9PJY5 ENST00000527473.5 ENST00000527392.5 ENST00000526062.5 H0YE59 H0YD60 E9PME1 E9PPS6 ENST00000531093.5 ENST00000527510.5 E9PII1 E9PMJ9 ENST00000533471.5 ENST00000530580.5 ENST00000530938.5 ENST00000534127.5 [P78524-1] E9PKM1 E9PN93 E9PI67 ENST00000530991.5 [P78524-3] ENST00000526057.5 ENST00000528196.5 E9PKV3 E9PRS6 E9PJP0 H0YDL0 ENST00000528523.5 ENST00000530593.5 B4DDL8 ENST00000530338.5 ENST00000531578.1 E9PLH6 E9PK36 E9PQA9 E9PM84 ENST00000534248.5 ENST00000533020.5 E9PKN3 E9PQM5 ENST00000533016.1 ENST00000532734.5 ENST00000530959.5 ENST00000527516.5 E9PMP1 E9PNM8 ENST00000313726.11 [P78524-1] ENST00000533225.5 ENST00000526155.5 E9PJC3 E9PQU6 ENST00000527347.5 ENST00000526099.5 ENST00000528527.5 ENST00000534665.5 E9PM32 |